POSA56 A Cost-Effectiveness Analysis of Polatuzumab in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Portugal
Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.201
https://www.valueinhealthjournal.com/article/S1098-3015(21)01996-3/fulltext
Section Title :
Section Order :
10968
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01996-3&doi=10.1016/j.jval.2021.11.201